Literature DB >> 395118

Chemical synthesis of [des(tetrapeptide B27--30), Tyr(NH2)26-B] and [des(pentapeptide B26--30), Phe(NH2)25-B] bovine insulins.

A Cosmatos, N Ferderigos, P G Katsoyannis.   

Abstract

Two analogs of bovine insulin, [des(tetrapeptide B27--30), Tyr(NH2)26-B] and [des(pentapeptide B26--30), Phe(NH2)25-B] insulin, which differ from the parent molecule in that the C-terminal tetrapeptide and pentapeptide sequences, respectively, from the B chain have been eliminated and the newly exposed residues are amidated, have been synthesized. The [des(tetrapeptide B27--30), Tyr(NH2)26-B] insulin shows potencies of 16.8 IU/mg by the mouse convulsion assay method and 10.8 IU/mg by the radioimmunoassay method. The [des(pentapeptide B26--30), Phe(NH2)25-B] insulin possesses a potency of 10.5 IU/mg when assayed by the mouse convulsion method and 14 IU/mg by the radioimmunoassay technique. The potencies of these analogs are higher than the potencies of the respective non-amidated derivatives (Katsoyannis et al., 1973, 1974). It is speculated that the gradual decline of biological activity observed as amino acid residues are eliminated from the C-terminal region of the B chain of insulin is due to the proximity of a hydrophilic carboxyl group to the hydrophobic core of the protein molecule.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 395118     DOI: 10.1111/j.1399-3011.1979.tb01957.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  9 in total

1.  Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.

Authors:  Daniel F Berenson; Allison R Weiss; Zhu-Li Wan; Michael A Weiss
Journal:  Ann N Y Acad Sci       Date:  2012-03-13       Impact factor: 5.691

2.  A highly potent insulin: des-(B26-B30)-[AspB10,TyrB25-NH2]insulin(human).

Authors:  G P Schwartz; G T Burke; P G Katsoyannis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Enhancing the activity of a protein by stereospecific unfolding: conformational life cycle of insulin and its evolutionary origins.

Authors:  Qing-xin Hua; Bin Xu; Kun Huang; Shi-Quan Hu; Satoe Nakagawa; Wenhua Jia; Shuhua Wang; Jonathan Whittaker; Panayotis G Katsoyannis; Michael A Weiss
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

Review 4.  A thing of beauty: Structure and function of insulin's "aromatic triplet".

Authors:  Michael A Weiss; Michael C Lawrence
Journal:  Diabetes Obes Metab       Date:  2018-09       Impact factor: 6.577

5.  Contribution of the B16 and B26 tyrosine residues to the biological activity of insulin.

Authors:  S Q Hu; G T Burke; P G Katsoyannis
Journal:  J Protein Chem       Date:  1993-12

6.  Protective hinge in insulin opens to enable its receptor engagement.

Authors:  John G Menting; Yanwu Yang; Shu Jin Chan; Nelson B Phillips; Brian J Smith; Jonathan Whittaker; Nalinda P Wickramasinghe; Linda J Whittaker; Vijay Pandyarajan; Zhu-li Wan; Satya P Yadav; Julie M Carroll; Natalie Strokes; Charles T Roberts; Faramarz Ismail-Beigi; Wieslawa Milewski; Donald F Steiner; Virander S Chauhan; Colin W Ward; Michael A Weiss; Michael C Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

7.  Acute metabolic actions of des-(B27-B30)-insulin and related analogues in adult rats.

Authors:  H Hartmann; J Korf; U Ottmers; W Creutzfeldt
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

8.  Contribution of TyrB26 to the Function and Stability of Insulin: STRUCTURE-ACTIVITY RELATIONSHIPS AT A CONSERVED HORMONE-RECEPTOR INTERFACE.

Authors:  Vijay Pandyarajan; Nelson B Phillips; Nischay Rege; Michael C Lawrence; Jonathan Whittaker; Michael A Weiss
Journal:  J Biol Chem       Date:  2016-04-26       Impact factor: 5.157

9.  Facile synthesis of insulin fusion derivatives through sortase A ligation.

Authors:  Maria M Disotuar; Jake A Smith; Jinze Li; Steve Alam; Nai-Pin Lin; Danny Hung-Chieh Chou
Journal:  Acta Pharm Sin B       Date:  2020-11-21       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.